Holen Sie sich die Stockscreener-App
180.92
0.63%
1.03
Handel nachbörslich:
180.92
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$179.89
Offen:
$179.28
24-Stunden-Volumen:
83,920
Relative Volume:
0.36
Marktkapitalisierung:
$3.55B
Einnahmen:
$152.42M
Nettoeinkommen (Verlust:
$45.24M
KGV:
72.08
EPS:
2.51
Netto-Cashflow:
$6.97M
1W Leistung:
-1.16%
1M Leistung:
+9.22%
6M Leistung:
+69.84%
1J Leistung:
+74.98%
1-Tages-Spanne:
$177.76
$182.13
1-Wochen-Bereich:
$177.35
$186.40
52-Wochen-Spanne:
$93.58
$186.40
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Firmenname
Ligand Pharmaceuticals Inc
Sektor
Branche
Telefon
858-550-7500
Adresse
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Vergleichen Sie LGND mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
180.92 | 3.51B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Eingeleitet | Stifel | Buy |
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-04-14 | Fortgesetzt | Stephens | Overweight |
| 2021-02-04 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-06 | Eingeleitet | Barclays | Overweight |
| 2020-03-24 | Herabstufung | Argus | Buy → Hold |
| 2020-03-10 | Eingeleitet | Guggenheim | Neutral |
| 2020-02-06 | Eingeleitet | The Benchmark Company | Buy |
| 2019-09-19 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-03 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-06 | Bestätigt | H.C. Wainwright | Buy |
| 2018-10-29 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2018-10-02 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-11 | Bestätigt | Argus | Buy |
| 2018-08-17 | Eingeleitet | Goldman | Neutral |
| 2018-08-08 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2018-06-21 | Eingeleitet | Argus | Buy |
| 2017-12-27 | Bestätigt | H.C. Wainwright | Buy |
| 2017-09-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-10-05 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-05 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2016-03-11 | Eingeleitet | Sidoti | Buy |
| 2016-03-03 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Ligand Pharmaceuticals Inc Aktie (LGND) Neueste Nachrichten
Is Ligand Pharmaceuticals Incorporated forming a reversal pattern2025 Sector Review & Risk Adjusted Buy and Sell Alerts - newser.com
Technical signs of recovery in Ligand Pharmaceuticals Incorporated2025 Big Picture & Verified Entry Point Signals - newser.com
Trend analysis for Ligand Pharmaceuticals Incorporated this weekJuly 2025 Levels & Weekly High Conviction Ideas - newser.com
Analyzing drawdowns of Ligand Pharmaceuticals Incorporated with statistical toolsVolume Spike & Reliable Entry Point Alerts - newser.com
Price action breakdown for Ligand Pharmaceuticals IncorporatedPortfolio Return Summary & Accurate Entry/Exit Alerts - newser.com
Can Ligand Pharmaceuticals Incorporated stock sustain market leadershipDividend Hike & Reliable Trade Execution Plans - newser.com
Combining price and volume data for Ligand Pharmaceuticals IncorporatedLayoff News & Stock Timing and Entry Methods - newser.com
Real time alert setup for Ligand Pharmaceuticals Incorporated performanceWall Street Watch & Real-Time Chart Breakout Alerts - newser.com
Can Ligand Pharmaceuticals Incorporated stock deliver sustainable ROEEarnings Beat & Technical Pattern Alert System - newser.com
Published on: 2025-10-12 10:25:04 - newser.com
Ligand Pharmaceuticals (LGND): Evaluating Valuation After FDA Green Light for Lasix ONYU’s At-Home Heart Failure Solution - simplywall.st
Villere ST Denis J & Co. LLC Has $32.64 Million Position in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Earns Sell (D+) Rating from Weiss Ratings - MarketBeat
Order flow analysis tools used on Ligand Pharmaceuticals IncorporatedPortfolio Performance Report & Consistent Profit Focused Trading Strategies - newser.com
How FDA Approval of Lasix ONYU Expands Ligand Pharmaceuticals' (LGND) Royalty Pipeline and Revenue Potential - simplywall.st
Ligand Pharmaceuticals Hits New 52-Week High of $186.40 - Markets Mojo
Ligand Partner SQ Innovation Gets FDA Approval for At-Home Edema Treatment for Heart Failure Patients - MarketScreener
Ligand (LGND) Gains FDA Approval for Lasix ONYU, Enhancing Heart Failure Treatment - GuruFocus
Ligand Pharmaceuticals Announces FDA Approval of Lasix ONYU, Innovative Subcutaneous Delivery Device for Edema Treatment in Heart Failure Patients - Quiver Quantitative
Ligand Pharmaceuticals Reaches Analyst Target Price - Nasdaq
Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients - GlobeNewswire Inc.
Is Ligand Pharmaceuticals Incorporated (LGDN) stock bottoming after sell off2025 Momentum Check & Reliable Intraday Trade Plans - newser.com
Risk adjusted return profile for Ligand Pharmaceuticals Incorporated analyzedGlobal Markets & Short-Term High Return Ideas - newser.com
Ligand Pharmaceuticals Hits New 52-Week High of $184.26 - Markets Mojo
Ligand Pharmaceuticals Hits New 52-Week High of $183.81 - Markets Mojo
What analysts say about Ligand Pharmaceuticals Incorporated LGDN stockStock Rotation Strategies & Access Insider-Level Stock Analysis - earlytimes.in
Ligand Pharmaceuticals (NASDAQ:LGND) Reaches New 1-Year HighHere's What Happened - MarketBeat
Ligand Pharmaceuticals stock hits 52-week high at $183.98 By Investing.com - Investing.com Canada
Hot Picks: Three mid-cap stock picks poised for growth amid strong sector tailwinds - BNN Bloomberg
How to read the order book for Ligand Pharmaceuticals IncorporatedEarnings Miss & Real-Time Volume Trigger Notifications - newser.com
Ligand Pharmaceuticals Hits New 52-Week High of $181.62 - Markets Mojo
Press Release: Ligand Reports First Quarter 2025 Financial Results - 富途牛牛
Insider Sell Alert: John Kozarich Sells Shares of Ligand Pharmac - GuruFocus
Ligand Pharmaceuticals (NASDAQ:LGND) Director John Kozarich Sells 467 Shares - MarketBeat
Ligand Pharmaceuticals Hits New 52-Week High at $177.77 - Markets Mojo
Ligand Pharmaceuticals IncorporatedEquity Right (LGNYZ) Price Target Increased by 410.53% to 0.05 - Nasdaq
Ligand Pharmaceuticals stock hits 52-week high at $172.49 By Investing.com - Investing.com Canada
Ligand Pharmaceuticals (NASDAQ:LGND) Reaches New 12-Month HighWhat's Next? - MarketBeat
What drives Ligand Pharmaceuticals Incorporated LGDN stock priceBollinger Bands Signals & Affordable Stock Market Tips - earlytimes.in
What drives Ligand Pharmaceuticals Incorporated stock priceHead and Shoulders Patterns & Small Budget Capital Gains - Early Times
Ligand Pharmaceuticals Hits New 52-Week High of $170.78 - Markets Mojo
Ligand Pharmaceuticals Hits New 52-Week High of $172.45 - Markets Mojo
Congress Asset Management Co. Raises Stake in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals director Aryeh sells $1.7 million in shares By Investing.com - Investing.com Australia
LGND: Ligand Pharmaceuticals Inks $11M Royalty Deal with Arecor - GuruFocus
Arecor Therapeutics announces royalty financing agreement with Ligand to raise up to $11 mln - MarketScreener
Ligand Pharmaceuticals director Aryeh sells $1.7 million in shares - Investing.com
Ligand Pharmaceuticals (NASDAQ:LGND) Hits New 12-Month HighTime to Buy? - MarketBeat
Finanzdaten der Ligand Pharmaceuticals Inc-Aktie (LGND)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):